• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ginkgo Bioworks Reports First Quarter 2025 Financial Results

    5/6/25 5:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email

    Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target

    Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems

    BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

    (PRNewsfoto/Ginkgo Bioworks)

    First Quarter 2025 Financial Results

    • First quarter 2025 Total revenue of $48 million, up from $38 million in the comparable prior year period, an increase of 27% primarily due to $7 million of non-cash revenue from the release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $41 million, an increase of 8% over the prior year period.
      • Excluding the $7 million non-cash deferred revenue release, first quarter 2025 Cell Engineering revenue of $31 million, up from $28 million in the comparable prior year period, an increase of 10%, primarily driven by growth with biopharma and government customers
      • First quarter 2025 Biosecurity revenue of $10 million, flat to $10 million in the comparable prior year period
    • First quarter 2025 GAAP net loss of $(91) million, compared to $(166) million in the comparable prior year period
    • First quarter 2025 Adjusted EBITDA of $(47) million, up from $(117) million in the comparable prior year period, driven by the increase in revenue as well as a decrease in operating expenses
    • Cash, cash equivalents and marketable securities balance as of March 31, 2025 of $517 million

    "We're starting the year on a solid base thanks to the significant restructuring efforts of the past year," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Our Solutions business has become a trusted R&D service provider to the US Government and biopharma industry, meanwhile our Tools businesses have traction with existing offerings and are positioned to meet emergent opportunities in areas like AI, which are driving demand for large scale biological datasets. Through all of this, we are maintaining our commitment to achieving our cost reduction targets."

    Recent Business Highlights & Strategic Positioning

    • Biotechnology remains a critical emerging technology area in the US and Ginkgo is well positioned to provide biosecurity and R&D services
      • Office of Science and Technology Policy (OSTP) Director Michael Kratsios and the National Security Commission on Emerging Biotechnology (NSCEB) report have both recently emphasized biotech as an area of national importance
      • We have 28 US Government projects across Cell Engineering and Biosecurity with ~$180M of contracted backlog and unfunded potential backlog
    • Ginkgo's Datapoints and Automation offerings are seeing new deals and opportunities emerging
      • Datapoints published GDPa1, an antibody developability dataset for 246 IgGs across 10 assays, generated using Ginkgo's high-throughput PROPHET-Ab platform
      • Automation signed a deal recently with Aura Genetics, our first diagnostics company customer
    • We made progress on our objective to reach Adjusted EBITDA breakeven by the end of 2026
      • Ginkgo's reduction in force and other cost cutting measures have achieved an annualized run-rate cost reduction of $205 million as of the first quarter of 2025, with a target to achieve $250 million in cost reduction by the end of the third quarter of 2025. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease.

    Full Year 2025 Guidance

    • Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; and Biosecurity revenue of at least $50 million.  Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $7 million non-cash deferred revenue release in the first quarter to:
      • Total revenue of $167-$187 million in 2025;
      • Cell engineering revenue of $117-$137 million in 2025; and
      • Biosecurity revenue of at least $50 million in 2025.

    Conference Call Details

    Ginkgo will host a videoconference today, Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the first quarter of 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.

    To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected].

    A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

    Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

    Audio-Only Dial Ins:

    +1 646 931 3860 (New York)

    +1 301 715 8592 (Washington DC)

    +1 305 224 1968 (Miami)

    +1 312 626 6799 (Chicago)

    +1 346 248 7799 (Houston)

    +1 408 638 0968 (San Jose)

    +1 564 217 2000 (Seattle)

    +1 689 278 1000 (Orlando)

    Webinar ID: 966 5095 4269

    If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

    About Ginkgo Bioworks

    Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats.  For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

    Forward-Looking Statements of Ginkgo Bioworks 

    This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, impacts of our restructuring, potential customer success, including successful application of our offerings by our customers, the regulatory landscape, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2025 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

    Use of Non-GAAP Financial Measures

    Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.

    Ginkgo Bioworks Contacts: 

    INVESTOR CONTACT:

    [email protected] 

    MEDIA CONTACT:

    [email protected] 

     

    Ginkgo Bioworks Holdings, Inc.

    Condensed Consolidated Balance Sheets

    (unaudited)

    (in thousands, except share data)





    As of March 31,



    As of December 31,



    2025



    2024

    Assets







    Current assets:







    Cash and cash equivalents

    $              312,420



    $              561,572

    Marketable securities

    204,502



    —

    Accounts receivable, net

    26,293



    21,857

    Accounts receivable - related parties

    877



    586

    Prepaid expenses and other current assets

    20,442



    18,729

    Total current assets

    564,534



    602,744

    Property, plant and equipment, net

    197,828



    203,720

    Operating lease right-of-use assets

    383,394



    394,435

    Investments

    32,173



    48,704

    Intangible assets, net

    68,756



    72,510

    Other non-current assets

    46,778



    55,336

    Total assets

    $           1,293,463



    $           1,377,449

    Liabilities and Stockholders' Equity







    Current liabilities:







    Accounts payable

    $                11,267



    $                14,169

    Deferred revenue

    33,653



    27,710

    Accrued expenses and other current liabilities

    70,747



    65,387

    Total current liabilities

    115,667



    107,266

    Non-current liabilities:







    Deferred revenue, net of current portion

    80,378



    98,783

    Operating lease liabilities, non-current

    434,561



    438,766

    Other non-current liabilities

    15,430



    16,576

    Total liabilities

    646,036



    661,391

    Commitments and contingencies







    Stockholders' equity:







    Preferred stock, $0.0001 par value

    —



    —

    Common stock, $0.0001 par value

    5



    5

    Additional paid-in capital

    6,576,786



    6,555,416

    Accumulated deficit

    (5,928,514)



    (5,837,557)

    Accumulated other comprehensive loss

    (850)



    (1,806)

    Total stockholders' equity

    647,427



    716,058

    Total liabilities and stockholders' equity

    $           1,293,463



    $           1,377,449

     

    Ginkgo Bioworks Holdings, Inc.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (unaudited)

    (in thousands, except share data)





    Three Months Ended March 31,



    2025



    2024

    Cell Engineering revenue

    $           38,230



    $           27,889

    Biosecurity revenue

    10,088



    10,055

    Total revenue

    48,318



    37,944

    Costs and operating expenses:







    Cost of Biosecurity revenue (1)

    7,957



    9,202

    Cost of other revenue (1)

    4,090



    —

    Research and development (1)

    70,923



    136,457

    General and administrative (1)

    49,043



    70,287

    Restructuring charges

    5,273



    —

    Total operating expenses

    137,286



    215,946

    Loss from operations

    (88,968)



    (178,002)

    Other income (expense):







    Interest income, net

    6,081



    11,711

    Loss on investments

    (3,693)



    (2,544)

    Change in fair value of warrant liabilities

    —



    940

    Other income (expense), net

    (4,289)



    2,015

    Total other income (expense)

    (1,901)



    12,122

    Loss before income taxes

    (90,869)



    (165,880)

    Income tax expense

    88



    31

    Net loss

    $          (90,957)



    $       (165,911)

    Net loss per share:







    Basic

    $              (1.68)



    $              (3.31)

    Diluted

    $              (1.68)



    $              (3.32)

    Weighted average common shares outstanding:







    Basic

    54,241,619



    50,111,460

    Diluted

    54,241,619



    50,133,366

    Comprehensive loss:







    Net loss

    $          (90,957)



    $       (165,911)

    Other comprehensive (loss) income:







    Foreign currency translation adjustment

    849



    (3,035)

    Unrealized gains on available-for-sale securities

    107



    —

    Total other comprehensive (loss) income

    956



    (3,035)

    Comprehensive loss

    $          (90,001)



    $       (168,946)



    (1)     Total stock-based compensation expense, inclusive of employer payroll taxes, was allocated as follows (in thousands):





    Three Months Ended March 31,



    2025



    2024

    Research and development

    $              9,184



    $           24,120

    General and administrative

    9,912



    18,277

    Cost of Biosecurity revenue

    735



    —

    Cost of other revenue

    969



    —

    Total

    $           20,800



    $           42,397

     

    Ginkgo Bioworks Holdings, Inc.

    Condensed Consolidated Statements of Cash Flows

    (unaudited)

    (in thousands)





    Three Months Ended March 31,



    2025



    2024

    Cash flows from operating activities:







    Net loss

    $         (90,957)



    $       (165,911)

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation and amortization

    15,366



    12,869

    Stock-based compensation

    20,431



    40,782

    Loss on investments

    3,693



    2,544

    Change in fair value of notes receivable

    5,285



    —

    Change in fair value of warrant liabilities

    —



    (940)

    Change in fair value of contingent consideration

    (1,302)



    (926)

    Non-cash lease expense

    7,379



    5,637

    Non-cash in-process research and development

    —



    16,816

    Other non-cash activity

    149



    (442)

    Changes in operating assets and liabilities:







    Accounts receivable

    (4,693)



    (6,770)

    Prepaid expenses and other current assets

    462



    1,154

    Operating lease right-of-use assets

    3,675



    —

    Other non-current assets

    (167)



    (707)

    Accounts payable, accrued expenses and other current liabilities

    6,419



    10,871

    Deferred revenue, current and non-current

    (12,471)



    (2,912)

    Operating lease liabilities, current and non-current

    (4,790)



    (4,097)

    Other non-current liabilities

    —



    2,773

    Net cash used in operating activities

    (51,521)



    (89,259)

    Cash flows from investing activities:







    Purchases of marketable debt securities

    (191,182)



    —

    Purchases of property and equipment

    (7,622)



    (6,710)

    Business acquisition

    —



    (5,400)

    Other

    120



    —

    Net cash used in investing activities

    (198,684)



    (12,110)

    Cash flows from financing activities:







    Proceeds from exercise of stock options

    —



    70

    Principal payments on finance leases

    (207)



    (294)

    Contingent consideration payment

    —



    (621)

    Net cash used in financing activities

    (207)



    (845)

    Effect of foreign exchange rates on cash and cash equivalents

    74



    (157)

    Net decrease in cash, cash equivalents and restricted cash

    (250,338)



    (102,371)









    Cash and cash equivalents, beginning of period

    561,572



    944,073

    Restricted cash, beginning of period

    44,171



    45,511

    Cash, cash equivalents and restricted cash, beginning of period

    605,743



    989,584









    Cash and cash equivalents, end of period

    312,420



    840,440

    Restricted cash, end of period

    42,985



    46,773

    Cash, cash equivalents and restricted cash, end of period

    $          355,405



    $          887,213

     

    Ginkgo Bioworks Holdings, Inc.

    Segment Information

    (in thousands, unaudited)







    Three Months Ended March 31,



    2025



    2024

    Cell Engineering







    Revenue

    $                38,230



    $                27,889

    Costs and operating expenses:







       Cost of other revenue

    3,121



    —

       Research and development

    48,670



    81,898

       General and administrative

    18,027



    38,244

    Cell Engineering operating loss

    (31,588)



    (92,253)

    Biosecurity







    Revenue

    10,088



    10,055

    Costs and operating expenses:







       Cost of Biosecurity revenue

    7,223



    9,202

       Research and development

    —



    120

       General and administrative

    8,050



    11,951

    Biosecurity operating loss

    (5,185)



    (11,218)

    Total segment operating loss

    (36,773)



    (103,471)

    Reconciling items to reconcile total segment operating loss to loss before income taxes:

    Stock-based compensation (1)

    20,800



    42,397

    Depreciation and amortization

    15,366



    12,869

    Restructuring charges (2)

    5,273



    —

    Carrying cost of excess space (net of sublease income) (3)

    11,674



    —

    Merger and acquisition related expense (income) (4)

    (918)



    2,394

    Acquired in-process research and development

    —



    16,871

    Other (income) expense, net (5)

    1,901



    (12,122)

    Loss before income taxes

    $              (90,869)



    $            (165,880)





    (1)

    Includes $0.4 million and $1.6 million in employer payroll taxes for the three months ended March 31, 2025 and 2024, respectively.





    (2)

    Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024.





    (3)

    The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.





    (4)

    Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs.





    (5)

    Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.

     

    Ginkgo Bioworks Holdings, Inc.

    Selected Non-GAAP Financial Measures

    (in thousands, unaudited)





    Three Months Ended March 31,

    (in thousands)

    2025



    2024

    Net loss (1)

    $          (90,957)



    $       (165,911)

    Interest income, net

    (6,081)



    (11,711)

    Income tax expense

    88



    31

    Depreciation and amortization

    15,366



    12,869

    EBITDA

    (81,584)



    (164,722)

    Stock-based compensation (2)

    20,800



    42,397

    Restructuring charges (3)

    5,273



    —

    Loss on investments

    3,693



    2,544

    Change in fair value of warrant liabilities

    —



    (940)

    Merger and acquisition related expense (income) (4)

    (918)



    2,394

    Change in fair value of convertible notes

    5,285



    1,326

    Adjusted EBITDA

    $          (47,451)



    $       (117,001)





    (1)

    All periods include non-cash revenue when earned, including $7.5 million in the three months ended March 31, 2025 recognized pursuant to the termination of revenue contracts with BiomEdit.





    (2)

    Includes $0.4 million and $1.6 million in employer payroll taxes for the three months ended March 31, 2025 and 2024, respectively.





    (3)

    Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024.





    (4)

    Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero and $16.9 million for the three months ended March 31, 2025 and 2024, respectively.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-first-quarter-2025-financial-results-302447788.html

    SOURCE Ginkgo Bioworks

    Get the next $DNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/16/24 5:08:50 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/14/24 5:16:23 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    SEC Filings

    See more
    • SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

      144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      5/21/25 4:11:12 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/21/25 4:07:27 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

      10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/6/25 5:04:29 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/14/24 4:31:49 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/12/24 3:58:52 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/4/24 11:56:06 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Financials

    Live finance-specific insights

    See more
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

      Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobiowor

      4/29/25 4:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

      Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial

      2/25/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Coen Steven P. sold $2,624 worth of shares (346 units at $7.58) and converted options into 743 shares, increasing direct ownership by 5% to 9,216 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/22/25 4:06:27 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Dmytruk Mark E. converted options into 1,479 shares and sold $5,355 worth of shares (706 units at $7.58), increasing direct ownership by 2% to 46,226 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/22/25 4:05:15 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Coen Steven P. sold $7,261 worth of shares (997 units at $7.28) and converted options into 1,804 shares, increasing direct ownership by 10% to 8,819 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      4/23/25 5:03:07 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

      BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

      5/21/25 4:05:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ginkgo Bioworks downgraded by BTIG Research

      BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

      5/15/24 7:33:13 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by William Blair

      William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

      5/10/24 7:33:29 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by Raymond James with a new price target

      Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

      11/14/23 9:04:22 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

      BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

      5/21/25 4:05:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

      Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

      5/14/24 6:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

      Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw

      4/8/24 7:00:00 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care